Abstract
Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19.
Highlights
Dear Editor, Coronavirus disease 2019 (COVID-19), which is caused by infection of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is currently a devastating threat to public health
It is intriguing to confirm it by performing in vitro competitive binding assays to demonstrate how efficient CR3022 is competing with the binding of SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2) and preventing the infection of cells with SARS-CoV-2 challenge
Another human monoclonal antibody S309 identified from a convalescent SARS patient was found to be able to bind with the S protein of SARS-CoV-2.5 The structure of S protein in complex with S309 is shown in Figure 2C and 2D
Summary
Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19. The vaccines induced immune responses and elicited high levels of neutralizing antibodies in a preclinical study.[10] The phase I clinical trial demonstrated its safety profile These studies demonstrate the potential of using the RBD domain in the SARS-CoV-2 for vaccine development and provide the preclinical evidence for the future clinical trials.[10] The advantage of this strategy is that there is no contagious virus to be handled, and adjuvants can enhance immunogenicity. The phase I clinical trial of an Ad5-vectored SARS-CoV2 vaccine was recently completed in Wuhan, China.[11] No serious adverse event was observed, and there was significantly increased levels of neutralizing antibodies after vaccination.[11] This important study demonstrates that the Ad5 vaccine induced the humoral response against SARSCoV-2, and its efficacy needs to be examined in the future clinical study Another adenovirus-vectored vaccine ChAdOx1 nCoV-19 was developed to express the antigen S protein of SARS-CoV-2.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
